Platelet Aggregation Pathway Network-Based Approach for Evaluating Compounds Efficacy

Table 2

Decrease of network efficiency and network flux, experimental results of each compound.

Compounds	Inhibition^a	NE decrease %	NF decrease %	Combination of NE and NF^d
Papaverine	0.67	45.5	79.8	61.8
Tirofiban^b	0.64	39.9	61.5	49.6
Deoxycholic acid	0.66	60.8	83.4	61.9
Scutellarin^c	0.51	52.1	77.9	57.8
Rhaponticin^c	0.65	42.8	65.6	47.3
Dipyridamole^b	0.60	41.8	74.1	55.6
Chrysin	0.68	47.9	75.5	65.6
Wogonin	0.67	55.6	68.7	58.8
Rhein	0.67	68.8	63.4	59.8
Silybin	0.73	56.6	96.6	71.6
Danshensu	0.57	32.2	43.4	38.3
Quercetin	0.67	47.9	89.7	76.7
Chlorogenic acid	0.54	34.6	37.9	38.6
Icariin^c	0.65	53.4	62.0	55.6
Quercitrin^c	0.57	41.8	60.0	50.1
Baicalin^c	0.61	55.3	62.2	54.9
Liquiritin^c	0.66	52.7	80.3	65.0
Salvianolic acid C	0.55	33.2	50.9	41.1
Kaempferol	0.63	50.4	71.9	60.3
Salvianolic acid B	0.53	25.0	22.8	23.9
Picroside II^c	0.51	24.7	68.8	44.6

^aThe inhibition effect determined in the final concentration of tested compounds was 34 𝜇M.
^bTirofiban and dipyridamole are two approved drugs.
^cThese seven molecules are glycoside compounds.
^dCombination of NE decrease and NF decrease: the square root of the product of the percentage of NE decrease and the percentage of NF decrease.